| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1992PNAS...89.2965W |
| P356 | DOI | 10.1073/PNAS.89.7.2965 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC48784 |
| https://europepmc.org/articles/PMC48784?pdf=render | ||
| P932 | PMC publication ID | 48784 |
| P698 | PubMed publication ID | 1557402 |
| P5875 | ResearchGate publication ID | 21599130 |
| P50 | author | Bert Vogelstein | Q827502 |
| P2093 | author name string | J. M. Ruppert | |
| A. J. Wong | |||
| S. H. Bigner | |||
| P. A. Humphrey | |||
| C. H. Grzeschik | |||
| D. S. Bigner | |||
| P2860 | cites work | An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs | Q22066003 |
| A simple and very efficient method for generating cDNA libraries | Q27860461 | ||
| Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells | Q29616544 | ||
| Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts | Q33556637 | ||
| Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma | Q33610591 | ||
| Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas | Q33881165 | ||
| A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors | Q33937136 | ||
| Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes | Q34162385 | ||
| Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification | Q34350623 | ||
| Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. | Q36599081 | ||
| Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors | Q36787477 | ||
| Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells | Q36903694 | ||
| Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene | Q37524558 | ||
| A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells | Q37554584 | ||
| An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide | Q40521534 | ||
| Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling | Q40649589 | ||
| Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy | Q40779148 | ||
| Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors | Q42054821 | ||
| Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells | Q42805935 | ||
| Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene | Q42806006 | ||
| Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines | Q42813360 | ||
| Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations | Q42819438 | ||
| Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein | Q44629218 | ||
| Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. | Q48088104 | ||
| The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription | Q48338976 | ||
| Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin | Q48536258 | ||
| Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 | ||
| Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. | Q55486297 | ||
| Clonal analysis using recombinant DNA probes from the X-chromosome | Q69904084 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm genes | Q70691924 |
| P304 | page(s) | 2965-2969 | |
| P577 | publication date | 1992-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Structural alterations of the epidermal growth factor receptor gene in human gliomas | |
| P478 | volume | 89 |
| Q42685037 | 3' end structure and rearrangements of EGFR in glioblastomas |
| Q93133060 | A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials |
| Q36414254 | A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies |
| Q46093038 | A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. |
| Q33811568 | A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor |
| Q38683823 | A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants |
| Q24647081 | A census of human cancer genes |
| Q98303321 | A compendium of mutational cancer driver genes |
| Q35211546 | A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice |
| Q40280414 | A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma |
| Q73046729 | A friendly signal |
| Q39168444 | A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance. |
| Q39496576 | A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency |
| Q35660849 | A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity |
| Q36010772 | A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors |
| Q42831336 | A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo |
| Q24293746 | A quantitative protein interaction network for the ErbB receptors using protein microarrays |
| Q35146077 | A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity |
| Q33888193 | A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor |
| Q35103401 | ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor |
| Q30155872 | ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking |
| Q27853013 | AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer |
| Q39411416 | Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. |
| Q31867049 | Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications |
| Q35838855 | Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases |
| Q36995979 | Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism |
| Q39346046 | Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". |
| Q45916176 | Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation. |
| Q38921652 | Advances and challenges: dendritic cell vaccination strategies for glioblastoma. |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q37527117 | Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. |
| Q55479603 | Alteration of c-fos gene methylation in human gliomas. |
| Q48877020 | Alterations of cell cycle regulators in gliomatosis cerebri |
| Q48462937 | Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival |
| Q33665884 | An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. |
| Q90215360 | An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments |
| Q34346944 | An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme |
| Q40859402 | An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex |
| Q27024830 | An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma |
| Q47974745 | Analysis of Constitutive EGFR Signaling Regulating IRF3 Transcriptional Activity in Cancer Cells |
| Q53465061 | Analysis of Epidermal Growth Factor Receptor Gene Amplification and Alteration in Stereotactic Biopsies of Brain Tumors |
| Q31037039 | Analysis of differentially expressed genes based on microarray data of glioma |
| Q34629812 | Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. |
| Q33795137 | Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma |
| Q64244828 | Anti-Invasion and Antiangiogenic Effects of Stellettin B through Inhibition of the Akt/Girdin Signaling Pathway and VEGF in Glioblastoma Cells |
| Q34120472 | Antibody-based immunotherapy for malignant glioma |
| Q88664225 | Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials |
| Q38990233 | Autophagy contributes to gefitinib-induced glioma cell growth inhibition. |
| Q26825496 | Biomarkers for glioma immunotherapy: the next generation |
| Q35576526 | Brain tumours: classification and genes |
| Q35812538 | Cancer therapeutics: understanding the mechanism of action |
| Q40120655 | Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma |
| Q37362563 | Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. |
| Q34983621 | Cellular mechanisms targeted during astrocytoma progression |
| Q36003118 | Cellular responses to EGFR inhibitors and their relevance to cancer therapy |
| Q30440490 | Cellular signaling molecules as therapeutic targets in glioblastoma multiforme |
| Q34285619 | Central role of the EGF receptor in neurometabolic aging |
| Q88580999 | Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors |
| Q38187480 | Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma |
| Q35800492 | Chaperone proteins and brain tumors: potential targets and possible therapeutics |
| Q42811147 | Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling |
| Q47561397 | Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications |
| Q28345662 | Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases |
| Q39770397 | Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies |
| Q30784536 | Clinical immunotherapy for brain tumors |
| Q33628302 | Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. |
| Q80100938 | Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma |
| Q39156727 | Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy. |
| Q35505109 | Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells |
| Q71646343 | Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue |
| Q35834190 | Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and nonrandom chromosomal gains and losses |
| Q35643021 | Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization |
| Q28083888 | Concepts of immunotherapy for glioma |
| Q42816271 | Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). |
| Q42450037 | Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor |
| Q41067751 | Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor |
| Q39933616 | Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators |
| Q37174174 | Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. |
| Q48112680 | Copy number alterations unmasked as enhancer hijackers |
| Q37256658 | Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma |
| Q38810064 | Current and future strategies for treatment of glioma |
| Q38313826 | Current challenges in designing GBM trials for immunotherapy |
| Q38012438 | Current clinical development of PI3K pathway inhibitors in glioblastoma |
| Q41611838 | Current perspectives in gliomas |
| Q26828965 | Current vaccine trials in glioblastoma: a review |
| Q92350809 | DNMT3A co-mutation in an IDH1-mutant glioblastoma |
| Q34584728 | Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab |
| Q42493708 | Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma |
| Q28087485 | Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme |
| Q26829873 | Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets |
| Q58126050 | Development and Analytical Validation of a BT-474 Anti-Proliferation Assay Targeting HER2 |
| Q33711627 | Development of an EGFRvIII specific recombinant antibody |
| Q54539724 | Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. |
| Q48961381 | Diagnosis of malignant glioma: role of neuropathology |
| Q36201368 | Differences in the skeletal muscle transcriptome profile associated with extreme values of fatty acids content |
| Q47200263 | Differential Characterization of Temozolomide-Resistant Human Glioma Cells. |
| Q42512929 | Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor |
| Q39068923 | Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth. |
| Q39354630 | Dissecting Pin1 and phospho-pRb regulation. |
| Q90103140 | Drosophila melanogaster as a Model System for Human Glioblastomas |
| Q37259602 | EGF receptor variant III as a target antigen for tumor immunotherapy |
| Q26853549 | EGFR Amplification and Glioblastoma Stem-Like Cells |
| Q39416297 | EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination? |
| Q54700951 | EGFR and EGFRvIII expression in primary breast cancer and cell lines. |
| Q33872371 | EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. |
| Q39578900 | EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis |
| Q36733618 | EGFR and HER2 signaling in breast cancer brain metastasis |
| Q37205334 | EGFR and KRAS mutations in patients with adenocarcinoma of the lung |
| Q40405623 | EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway |
| Q24338526 | EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma |
| Q38171032 | EGFR signaling and autophagy dependence for growth, survival, and therapy resistance |
| Q34016908 | EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing |
| Q36780907 | EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis |
| Q30456087 | EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance |
| Q37686698 | EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery |
| Q64120766 | EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma |
| Q38261455 | EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. |
| Q39314446 | EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. |
| Q38765219 | EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. |
| Q89748217 | EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma |
| Q50335608 | EGFRvIII-mediated radioresistance through a strong cytoprotective response. |
| Q35145144 | EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma |
| Q33758459 | EGFRvIII-targeted vaccination therapy of malignant glioma |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q37369449 | Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. |
| Q39953614 | Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells |
| Q33890758 | Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer |
| Q37025105 | Emerging immunotherapies for glioblastoma |
| Q36616502 | Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR |
| Q37544152 | Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases |
| Q34105339 | Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance |
| Q39584506 | Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. |
| Q41718736 | Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials |
| Q27865182 | Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain |
| Q46679323 | Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors |
| Q35782309 | Epidermal growth factor receptor expression in oligodendroglial tumors. |
| Q88485834 | Epidermal growth factor receptor in glioblastoma |
| Q48463583 | Epidermal growth factor receptor in proliferating reactive glia following transient focal ischemia in the rat brain |
| Q36504349 | Epidermal growth factor receptor inhibition and non-small cell lung cancer |
| Q39472366 | Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation |
| Q40759593 | Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype |
| Q30164745 | Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization |
| Q34589789 | Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors |
| Q30450853 | Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways |
| Q40038133 | Epidermal growth factor receptor-targeted therapy. |
| Q40641352 | Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand |
| Q37301207 | Epigenetic markers in human gliomas: prospects for therapeutic intervention |
| Q37970020 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective |
| Q33959306 | ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling |
| Q39121775 | Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. |
| Q41908287 | Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer |
| Q31045910 | Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis |
| Q33923950 | Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses |
| Q38781031 | ExRNA in Biofluids as Biomarkers for Brain Tumors |
| Q37038397 | Exomic sequencing of four rare central nervous system tumor types |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q35669708 | Expression of EGFRvIII in glioblastoma: prognostic significance revisited |
| Q41811462 | Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas |
| Q33941154 | Expression of the neural RNA-binding protein Musashi1 in human gliomas |
| Q36006446 | Extracellular RNAs: development as biomarkers of human disease |
| Q44559511 | Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans |
| Q35237503 | Extracellular molecules involved in cancer cell invasion |
| Q38309871 | FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer. |
| Q92632517 | Factors That Govern the Induction of Long-Lived Antibody Responses |
| Q64883724 | Fire in the Smoke: Battling Brain Tumors. |
| Q55093479 | From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. |
| Q28186796 | Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) |
| Q26825769 | G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues |
| Q37694758 | GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity |
| Q39509236 | Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation |
| Q40961519 | Gene amplification in human gliomas |
| Q83139511 | Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma |
| Q35553140 | Gene therapy of gliomas |
| Q34984218 | Genetic alterations associated with adult diffuse astrocytic tumors |
| Q38161344 | Genetic alterations in glioma |
| Q35117832 | Genetic alterations of human brain tumors as molecular prognostic factors |
| Q36021580 | Genetic and hypoxic regulation of angiogenesis in gliomas |
| Q36115735 | Genetic changes in squamous cell lung cancer: a review |
| Q34291055 | Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population |
| Q37348716 | Genetically engineered mouse models of brain cancer and the promise of preclinical testing |
| Q40686977 | Genetics of primary brain tumors: a review |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q48365352 | Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway |
| Q39908058 | Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress |
| Q38460865 | Glioblastoma: pathology, molecular mechanisms and markers |
| Q33746514 | Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science |
| Q34366431 | Glioma models |
| Q37752381 | Glioma stem cell signaling: therapeutic opportunities and challenges |
| Q34186001 | Gliomagenesis: genetic alterations and mouse models |
| Q38983559 | Glutamate and α-ketoglutarate: key players in glioma metabolism |
| Q27863678 | Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells |
| Q34722415 | Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma |
| Q55476334 | Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. |
| Q34105503 | Growth inhibition of glioblastoma cells by human Pur(alpha). |
| Q35627691 | Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma |
| Q39679566 | Helianthin induces antiproliferative effect on human glioblastoma cells in vitro |
| Q92811985 | Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival |
| Q33721106 | Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies |
| Q46581912 | Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors |
| Q24648948 | IDH1 and IDH2 mutations in gliomas |
| Q53890346 | INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma. |
| Q24650927 | Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway |
| Q40198860 | Identification of a novel EGF-sensitive cell cycle checkpoint |
| Q34168243 | Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas |
| Q40568272 | Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor |
| Q28389919 | Immunoglobulin genes implicated in glioma risk |
| Q39399928 | Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. |
| Q34488771 | Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma |
| Q38358124 | Immunotherapeutic advancements for glioblastoma. |
| Q35778576 | Immunotherapeutic strategies for malignant glioma |
| Q26866513 | Immunotherapy advances for glioblastoma |
| Q42396502 | Immunotherapy for glioblastoma: are we finally getting closer? |
| Q56890737 | Immunotherapy in Glioblastoma |
| Q36162929 | Immunotherapy of malignant brain tumors |
| Q43851121 | Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate |
| Q36081599 | In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q35374492 | Innovative Therapies against Human Glioblastoma Multiforme |
| Q40684830 | Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. |
| Q38303924 | Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. |
| Q54289713 | Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B. |
| Q35831012 | Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations |
| Q38829322 | Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses |
| Q35859194 | Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions. |
| Q33808359 | Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression |
| Q30425201 | Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib |
| Q59159123 | Lipoprotein-Based Nanoplatforms for Cancer Molecular Imaging |
| Q41144733 | Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. |
| Q55475127 | Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. |
| Q30495880 | MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. |
| Q37432305 | Mammalian target of rapamycin (mTOR) pathways in neurological diseases |
| Q37476857 | Management of newly diagnosed glioblastoma: guidelines development, value and application |
| Q88371746 | Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development |
| Q91592481 | Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM |
| Q38786526 | Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers |
| Q40554514 | Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation |
| Q28473229 | Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma |
| Q34283477 | Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. |
| Q36734908 | Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model |
| Q35104265 | Molecular abnormalities and correlations with tumor response and outcome in glioma patients |
| Q36478640 | Molecular biology of human gliomas |
| Q26822717 | Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date |
| Q32062433 | Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases |
| Q41687849 | Molecular neuropathology of astrocytic brain tumors |
| Q36021558 | Molecular pathogenesis of astrocytic tumours |
| Q37858944 | Molecular subclassification of diffuse gliomas: seeing order in the chaos |
| Q33911283 | Molecular targeting of glioblastoma: Drug discovery and therapies |
| Q33644407 | Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies |
| Q36135157 | Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor |
| Q36032533 | Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma |
| Q40568043 | Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin |
| Q28365260 | Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway |
| Q44454339 | N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At |
| Q38070655 | Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extracellular particles |
| Q36081073 | New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells |
| Q89759447 | Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer |
| Q53616086 | Novel amplicons on the short arm of chromosome 7 identified using high resolution array CGH contain over expressed genes in addition to EGFR in glioblastoma multiforme. |
| Q48647863 | Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene |
| Q39043417 | Novel vaccines for glioblastoma: clinical update and perspective |
| Q30416775 | Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter |
| Q37115208 | Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis |
| Q55476021 | Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. |
| Q33943421 | Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy |
| Q38017366 | Oncogenic regulation of tissue factor and thrombosis in cancer |
| Q53803471 | Overexpression of the epidermal growth factor receptor confers migratory properties to nonmigratory postnatal neural progenitors. |
| Q38003175 | PDGF and PDGF receptors in glioma. |
| Q35080265 | PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo |
| Q34164924 | PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas |
| Q46592704 | PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells |
| Q37808385 | PI3Kinase signaling in glioblastoma |
| Q24650475 | PTPmu suppresses glioma cell migration and dispersal |
| Q93104522 | Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue |
| Q40633474 | Pathophysiology of glial growth factor receptors |
| Q33346827 | Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma |
| Q33834813 | Phenotype vs genotype in the evolution of astrocytic brain tumors |
| Q30434083 | Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. |
| Q30393905 | Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells |
| Q72007934 | Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta |
| Q37579647 | Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer |
| Q42834600 | Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor |
| Q48347971 | Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. |
| Q38107462 | Progress on molecular biomarkers and classification of malignant gliomas |
| Q55480092 | Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. |
| Q58700626 | Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma |
| Q38748694 | Prospect of rindopepimut in the treatment of glioblastoma. |
| Q34507561 | Prospects for gene-engineered T cell immunotherapy for solid cancers. |
| Q34627812 | Proteases and the biology of glioma invasion |
| Q41679383 | Protein tyrosine kinases and cancer |
| Q34303359 | Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells |
| Q55457286 | Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? |
| Q40484644 | RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. |
| Q38431453 | Radiation therapy for glioma stem cells |
| Q48238155 | Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor |
| Q35659088 | Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors |
| Q37701607 | Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts |
| Q26752579 | Radioresistance of Brain Tumors |
| Q35624032 | Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor |
| Q38398440 | ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. |
| Q34789569 | Reassessing target antigens for adoptive T-cell therapy |
| Q42004592 | Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). |
| Q38130137 | Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung |
| Q36321176 | Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma |
| Q100750414 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma |
| Q33775591 | Relationships linking amplification level to gene over-expression in gliomas |
| Q34201954 | Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents |
| Q54640393 | Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. |
| Q36414279 | Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging |
| Q37775494 | Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme. |
| Q38534723 | Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? |
| Q38245925 | Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme |
| Q38051323 | Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma |
| Q52663432 | Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. |
| Q40038376 | SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients |
| Q36351195 | STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3 |
| Q34480613 | Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. |
| Q44526164 | Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells |
| Q37847104 | Signal transduction inhibitors and antiangiogenic therapies for malignant glioma |
| Q40872114 | Signal transduction pathways and their relevance in human astrocytomas |
| Q35987785 | Signaling multiplex of the epidermal growth factor receptor |
| Q40472879 | Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci |
| Q38218129 | Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. |
| Q26750970 | Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance |
| Q28732052 | Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma |
| Q41270902 | Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibody |
| Q37930388 | Standard of care therapy for malignant glioma and its effect on tumor and stromal cells |
| Q26771706 | Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) Concepts |
| Q27678732 | Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains |
| Q36683851 | Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6 |
| Q55363919 | Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. |
| Q52682275 | T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. |
| Q33700160 | Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases |
| Q38752350 | Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma. |
| Q64242208 | Target selection of CAR T cell therapy in accordance with the TME for solid tumors |
| Q94545537 | Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells |
| Q37981764 | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. |
| Q37405633 | Targeting EGFR resistance networks in head and neck cancer. |
| Q42602597 | Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. |
| Q37736255 | Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma |
| Q38233105 | Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. |
| Q27022941 | Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma |
| Q33574021 | Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors |
| Q36564975 | Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. |
| Q38598710 | The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors |
| Q41738022 | The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands |
| Q42448523 | The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. |
| Q33957440 | The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells |
| Q24657924 | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo |
| Q41687874 | The autocrine loop of TGF-alpha/EGFR and brain tumors |
| Q34949693 | The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells |
| Q38349130 | The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling |
| Q34610495 | The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications |
| Q27015045 | The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered |
| Q38255481 | The future of glioblastoma therapy: synergism of standard of care and immunotherapy |
| Q35114090 | The future of high-grade glioma: Where we are and where are we going |
| Q38248990 | The genetic signatures of pediatric high-grade glioma: no longer a one-act play |
| Q35210456 | The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors |
| Q35120839 | The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery |
| Q38155656 | The molecular landscape of diffuse glioma and prospects for biomarker development |
| Q29614654 | The mutational landscape of head and neck squamous cell carcinoma |
| Q28118814 | The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines |
| Q40491226 | The polymerase chain reaction: Application to nervous system disease |
| Q28144437 | The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling |
| Q34267620 | The receptor tyrosine kinases: role in cancer progression. |
| Q51416808 | The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. |
| Q38132400 | The role of epidermal growth factor receptor in cancer metastasis and microenvironment |
| Q38204718 | The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline |
| Q34775279 | The tumor suppressor CDKN3 controls mitosis |
| Q34325749 | The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy |
| Q91675856 | Theranostic Nanomedicine for Malignant Gliomas |
| Q35341639 | Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma |
| Q42139529 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation |
| Q57092293 | Tissue, cell and stage specificity of (epi)mutations in cancers |
| Q37533657 | Toward effective immunotherapy for the treatment of malignant brain tumors |
| Q36083914 | Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. |
| Q27329613 | Transmigration of neural stem cells across the blood brain barrier induced by glioma cells |
| Q33243912 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol |
| Q40758885 | Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor |
| Q38312987 | Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma |
| Q40596817 | Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. |
| Q40961498 | Tumor antigens in astrocytic gliomas |
| Q37186248 | Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma |
| Q26741318 | Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications |
| Q38303832 | Tyrosine kinase activity may be necessary but is not sufficient for c-erbB1-mediated tissue-specific tumorigenicity |
| Q35589206 | Tyrosine kinase inhibitors as cancer therapy |
| Q35162055 | Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors |
| Q27860884 | Untangling the ErbB signalling network |
| Q38081910 | Vaccine strategies for glioblastoma: progress and future directions |
| Q38243975 | Vaccine therapies for patients with glioblastoma |
| Q26829328 | Vaccine therapies in malignant glioma |
| Q38826168 | Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy |
| Q33951992 | What role(s) for TGFalpha in the central nervous system? |
| Q38053857 | What underlies the diversity of brain tumors? |
| Q38882167 | Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways |
| Q30303932 | c-Src, receptor tyrosine kinases, and human cancer |
| Q38099450 | iNOS: a potential therapeutic target for malignant glioma |
| Q40407116 | mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma |
Search more.